Lin Mei Selected Research

Agrin

1/2021	Characterization of LRP4/Agrin Antibodies From a Patient With Myasthenia Gravis.
1/2020	Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study.
12/2019	A Case of Triple-Negative Myasthenia Gravis Lambert-Eaton Overlap Syndrome With Negative Agrin and LRP-4 Antibodies.
1/2019	A mechanism in agrin signaling revealed by a prevalent Rapsyn mutation in congenital myasthenic syndrome.
1/2018	Induction of Anti-agrin Antibodies Causes Myasthenia Gravis in Mice.
1/2018	Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis.
6/2017	Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.
1/2017	Agrin to YAP in Cancer and Neuromuscular Junctions.
1/2017	Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients.
10/2014	LRP4 is critical for neuromuscular junction maintenance.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lin Mei Research Topics

Disease

126	Neoplasms (Cancer) 03/2024 - 07/2009
21	Breast Neoplasms (Breast Cancer) 12/2023 - 09/2009
16	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 11/2004
15	Schizophrenia (Dementia Praecox) 01/2023 - 06/2008
12	Myasthenia Gravis 01/2021 - 04/2012
12	Uterine Cervical Neoplasms (Cancer of the Cervix) 09/2019 - 12/2012
10	Neoplasm Metastasis (Metastasis) 12/2023 - 01/2014
10	Carcinogenesis 01/2021 - 08/2011
8	Wounds and Injuries (Trauma) 11/2023 - 12/2013
7	Hepatocellular Carcinoma (Hepatoma) 11/2022 - 12/2013
6	Inflammation (Inflammations) 12/2023 - 09/2010
6	Hyperthermia 02/2023 - 01/2020
6	Lung Neoplasms (Lung Cancer) 01/2019 - 04/2015
5	Hypoxia (Hypoxemia) 01/2020 - 09/2010
5	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 05/2011
4	Mental Disorders (Mental Disorder) 01/2023 - 03/2013
4	Congenital Myasthenic Syndromes (Myasthenia Gravis, Congenital) 01/2021 - 10/2014
4	Liver Neoplasms (Liver Cancer) 05/2018 - 09/2014
4	Muscle Weakness 01/2018 - 12/2013
3	Osteoarthritis 03/2024 - 12/2018
3	Pain (Aches) 05/2023 - 10/2013
3	Autism Spectrum Disorder 01/2023 - 01/2018
3	Infections 12/2022 - 01/2019
3	Stomach Neoplasms (Stomach Cancer) 10/2022 - 01/2020
3	Bone Resorption 06/2021 - 07/2008
3	Glioma (Gliomas) 10/2020 - 08/2011
3	Bacterial Infections (Bacterial Infection) 01/2020 - 05/2014

Drug/Important Bio-Agent (IBA)

38	Proteins (Proteins, Gene)FDA Link 10/2023 - 02/2007
23	tocophersolanIBA 09/2019 - 05/2010
20	Docetaxel (Taxotere)FDA Link 09/2019 - 07/2009
14	polydopamineIBA 07/2023 - 01/2016
14	AntibodiesIBA 01/2021 - 04/2012
13	AgrinIBA 01/2021 - 10/2008
13	Succinic Acid (Succinate)IBA 09/2019 - 05/2010
12	Phosphorus (Red Phosphorus)IBA 04/2022 - 01/2017
12	neogeninIBA 01/2021 - 11/2005
12	polyethylene glycol 1000IBA 09/2019 - 05/2010
11	Doxorubicin (Adriamycin)FDA LinkGeneric 07/2023 - 04/2015
9	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2023 - 02/2013
9	PolymersIBA 03/2021 - 11/2013
8	Therapeutic UsesIBA 12/2023 - 01/2014
8	VaccinesIBA 01/2023 - 04/2013
8	Small Interfering RNA (siRNA)IBA 01/2023 - 08/2011
7	HydrogelsIBA 07/2023 - 05/2014
7	Peptides (Polypeptides)IBA 01/2023 - 05/2011
7	LigandsIBA 01/2022 - 04/2006
7	Neuregulin-1 (Neuregulin 1)IBA 01/2018 - 06/2008
6	MicroRNAs (MicroRNA)IBA 10/2022 - 01/2018
6	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2007
6	Silicon Dioxide (Silica)FDA LinkGeneric 10/2021 - 02/2016
6	Messenger RNA (mRNA)IBA 01/2021 - 01/2015
6	caprolactoneIBA 10/2015 - 09/2009
5	Folic Acid (Vitamin M)FDA LinkGeneric 04/2024 - 06/2015
5	polypyrroleIBA 03/2024 - 01/2022
5	Polyglactin 910IBA 12/2022 - 05/2010
5	Netrin ReceptorsIBA 01/2021 - 11/2004
5	NetrinsIBA 01/2021 - 01/2008
5	Polylactic Acid-Polyglycolic Acid CopolymerIBA 01/2020 - 11/2013
5	NanocapsulesIBA 01/2019 - 01/2017
5	muskIBA 01/2018 - 10/2008
5	LDL Receptors (LDL Receptor)IBA 01/2018 - 12/2013
5	Poloxamer (Poloxamer 407)IBA 06/2010 - 06/2009
4	Adenosine Triphosphate (ATP)IBA 03/2024 - 01/2018
4	1-phenyl-3,3-dimethyltriazene (PDT)IBA 11/2023 - 01/2022
4	MicellesIBA 11/2023 - 11/2014
4	Hyaluronic Acid (Hyaluronan)IBA 07/2023 - 01/2014
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2018
4	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2019
4	CytokinesIBA 01/2023 - 06/2008
4	Granzymes (Granzyme)IBA 12/2022 - 11/2015
4	Ethylene Glycol (Monoethylene Glycol)IBA 12/2022 - 09/2014
4	Amyloid (Amyloid Fibrils)IBA 06/2021 - 05/2011
4	RNA (Ribonucleic Acid)IBA 10/2020 - 01/2015
4	Protein Isoforms (Isoforms)IBA 01/2019 - 09/2007
4	ErbB Receptors (EGF Receptor)IBA 01/2019 - 01/2012
4	Cholic AcidIBA 07/2015 - 08/2013
4	Prostaglandins AIBA 01/2015 - 10/2011
3	EnzymesIBA 03/2024 - 01/2019
3	Glucose (Dextrose)FDA LinkGeneric 03/2024 - 08/2004
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2024 - 01/2018
3	Dopamine (Intropin)FDA LinkGeneric 11/2023 - 01/2023
3	NanogelsIBA 07/2023 - 01/2017
3	Hydroxyl RadicalIBA 02/2023 - 01/2021
3	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2023 - 06/2015
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2023 - 10/2014
3	UbiquitinIBA 01/2023 - 09/2009
3	Biocompatible Materials (Biomaterials)IBA 10/2021 - 11/2013
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021 - 08/2011
3	ParvalbuminsIBA 01/2021 - 12/2011
3	Glutamic Acid (Glutamate)FDA Link 01/2021 - 01/2018
3	TensinsIBA 01/2021 - 08/2011

Therapy/Procedure

77	Therapeutics 02/2024 - 06/2008
31	Drug Therapy (Chemotherapy) 02/2024 - 09/2009
16	Immunotherapy 01/2024 - 01/2013
11	Photothermal Therapy 10/2023 - 10/2018
7	Quantum Dots (Quantum Dot) 03/2021 - 01/2019
6	Lasers (Laser) 03/2024 - 09/2014
4	Precision Medicine 04/2022 - 01/2017
3	Photochemotherapy (Photodynamic Therapy) 11/2023 - 01/2022
3	Radiotherapy 11/2022 - 01/2012